<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407548</url>
  </required_header>
  <id_info>
    <org_study_id>SunYat-senU002</org_study_id>
    <nct_id>NCT02407548</nct_id>
  </id_info>
  <brief_title>The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia</brief_title>
  <acronym>TEDSCD</acronym>
  <official_title>The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In previous study the investigators found that CoQ10 can improve cholesterol efflux from
      macrophages in cell model, ApoE mice model and small-scale of healthy volunteers. In
      addition, CoQ10 has strong antioxidant activity and is an essential factor of mitochondria
      electron transport chain. So the investigators hypothesize that CoQ10 may have some health
      promotion effect on dyslipidemia, risk factor of atherosclerosis and other cardiovascular
      diseases. On this purpose, the investigators are going to recruit 150 dyslipidemia patients
      to supply CoQ10+vitamin E or CoQ10 alone or placebo in different doses for 24 weeks to
      explore the effects of CoQ10 on cholesterol efflux and lipid profiles on dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of CoQ10 on lipid profile</measure>
    <time_frame>6 months</time_frame>
    <description>Tg, Tc, LDL, HDL, APOA1,APOB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on blood glucose and insulin</measure>
    <time_frame>6 mouth</time_frame>
    <description>reflect insulin sensibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on oxidative stress and inflammation</measure>
    <time_frame>6 mouth</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effects of CoQ10 on FGF21</measure>
    <time_frame>6 month</time_frame>
    <description>reflect glucose and lipid metabolism</description>
  </other_outcome>
  <other_outcome>
    <measure>Effects of CoQ10 on cholesterol efflux from macrophages</measure>
    <time_frame>6 month</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>combined group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoQ10 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10 vitamin E softgel</intervention_name>
    <description>4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>combined group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10 softgel</intervention_name>
    <description>4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>CoQ10 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo softgel</intervention_name>
    <description>4 placebo softgels per day. Keep normal lift style unchanged.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects were considered to have dyslipidemia if they met 2 of the following 4
             criteria:

               -  fasting total cholesterol concentration&gt;200 mg/dL,

               -  fasting triglyceride concentration&gt;150mg/dL,

               -  fasting LDL-cholesterol concentrations&gt;100 mg/dL, or

               -  fasting HDL-cholesterol concentrations&gt;40 mg/dL.

        Exclusion Criteria:

          -  history of CVD or other severe chronic disease or use of any drugs known to affect
             lipid metabolism.

          -  use any antioxidant such as Vitamin E, vitamin C,Phytochemicals and coenzyme Q10
             within two months before trial.

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ling wenhua, professor</last_name>
    <role>Study Director</role>
    <affiliation>SUN YAY-SEN UNIVERSITY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hongshan Street community health service centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>zhangpeiwen</investigator_full_name>
    <investigator_title>PhD candidate</investigator_title>
  </responsible_party>
  <keyword>cholesterol efflux</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

